Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218202

SCHEMBL23218202

SCHEMBL23218202

CCOC(=O)c1coc2c(OCC3CC3)cc(Br)cc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 3/20 0.44
▸ PIM2 Q9P1W9 3/20 0.44
▸ CNR2 P34972 2/20 0.42
▸ OPRK1 P41145 5/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ MAOB P27338 1/20 0.37
▸ GABRA1 P14867 1/20 0.37
▸ GABRB1 P18505 1/20 0.37
▸ GABRA3 P34903 1/20 0.37
▸ GABRB2 P47870 1/20 0.37
▸ LMNA P02545 2/20 0.35
▸ F2 P00734 1/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852520 1.00 PIM1 (0.44) PIM1PIM2CNR2OPRK1ALDH1A1
SCHEMBL29852626 0.85 KDM4E (0.42) ALDH1A1SMN1; SMN2TSHRKDM4EMAPT
SCHEMBL28736179 0.85 KDM4E (0.42) ALDH1A1SMN1; SMN2TSHRKDM4EMAPT
SCHEMBL23228979 0.85 KDM4E (0.42) ALDH1A1SMN1; SMN2TSHRKDM4EMAPT
SCHEMBL23218364 0.83 PIM1 (0.42) PIM1PIM2CNR2ALDH1A1SMN1; SMN2
SCHEMBL29852968 0.83 PIM1 (0.42) PIM1PIM2CNR2ALDH1A1SMN1; SMN2
SCHEMBL21954323 0.82 ALDH1A1 (0.43) PIM1ALDH1A1SMN1; SMN2MAOBGABRA1
SCHEMBL29853188 0.82 ALDH1A1 (0.43) PIM1ALDH1A1SMN1; SMN2MAOBGABRA1
SCHEMBL23218621 0.81 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MAOBGABRA1GABRB1
SCHEMBL29853126 0.81 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MAOBGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PIM1 4538/4885PIM2 4286/4885CNR2 312/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PIM1 4497/4885PIM2 4673/4885CNR2 2888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.